381 related articles for article (PubMed ID: 19488076)
1. Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer L; Egle A; Hartmann TN; Greil R
Nat Rev Clin Oncol; 2009 Jul; 6(7):405-18. PubMed ID: 19488076
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
3. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
4. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
Schriever F; Huhn D
Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
[TBL] [Abstract][Full Text] [Related]
5. Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
Shukla A; Shukla V; Joshi SS
Leuk Lymphoma; 2018 Jul; 59(7):1565-1573. PubMed ID: 28882083
[TBL] [Abstract][Full Text] [Related]
6. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
[TBL] [Abstract][Full Text] [Related]
7. How will B-cell-receptor-targeted therapies change future CLL therapy?
Jones JA; Byrd JC
Blood; 2014 Mar; 123(10):1455-60. PubMed ID: 24394667
[TBL] [Abstract][Full Text] [Related]
8. Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge.
Smolej L
Curr Cancer Drug Targets; 2016; 16(8):701-709. PubMed ID: 27055577
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of alemtuzumab in chronic lymphocytic leukemia.
Nabhan C
Clin Lymphoma Myeloma; 2005 Sep; 6(2):115-21. PubMed ID: 16231849
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic lymphocytic leukemia.
Faderl SJ; Keating MJ
Curr Hematol Rep; 2005 Jan; 4(1):31-8. PubMed ID: 15610657
[TBL] [Abstract][Full Text] [Related]
11. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
Mato A; Jauhari S; Schuster SJ
Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
[TBL] [Abstract][Full Text] [Related]
12. Novel immune-based treatment strategies for chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Keating MJ
J Clin Oncol; 2005 Sep; 23(26):6325-32. PubMed ID: 16155015
[TBL] [Abstract][Full Text] [Related]
13. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
16. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M
Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
[TBL] [Abstract][Full Text] [Related]
17. Advances in the use of alemtuzumab in CLL.
Stilgenbauer S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
[No Abstract] [Full Text] [Related]
18. Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study.
Kater AP; Tonino SH
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10 Suppl 1():S34-41. PubMed ID: 20529806
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
20. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
Hillmen P
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]